Cerebrovia Therapeutics Ltd is developing CNS therapeutics for patients with persistent neurological symptoms following concussion, clinically recognised as mild traumatic brain injury.

Our lead programme targets neuroinflammation and trauma-linked neurological dysfunction - a major unmet clinical need where current care remains largely symptom-directed.

With a patent-protected therapeutic approach, defined biological rationale and human clinical case evidence, Cerebrovia is advancing toward formal controlled clinical evaluation and engaging investors and strategic partners.

Patent-protected programme | Human clinical case evidence | Preparing controlled clinical evaluation